Hua Medicine (Shanghai) Full Year 2023 Earnings: Misses Expectations

Hua Medicine (Shanghai) (HKG:2552) Full Year 2023 Results

Key Financial Results

• Revenue: CN¥76.6m (up 335% from FY 2022).
• Net loss: CN¥211.2m (loss widened by 3.8% from FY 2022).
• CN¥0.22 loss per share (further deteriorated from CN¥0.21 loss in FY 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Hua Medicine (Shanghai) Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 42%. Earnings per share (EPS) was also behind analyst expectations.

Looking ahead, revenue is forecast to grow 86% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Hong Kong.

Performance of the Hong Kong Pharmaceuticals industry.

The company's shares are down 7.0% from a week ago.

Balance Sheet Analysis

While earnings are important, another area to consider is the balance sheet. We have a graphic representation of Hua Medicine (Shanghai)'s balance sheet and an in-depth analysis of the company's financial position.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.